At a glance
ClinicalIndex Comparison RecordPhase 1Not Yet Recruiting· 15 target
Drug / intervention
GK01 injectiondrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Phase I, Open-label, Single-arm Clinical Study of GK01 Cell Injection in Patients With Advanced Malignant Solid Tumors
In Brief
A Phase 1 clinical trial evaluating GK01 injection for Advanced Solid Tumors. Not yet recruiting, targeting 15 participants across 1 site.
Detailed Summary
An Open-label, Single-arm, Phase I Clinical Study of GK01 Cell Injection in the Treatment of Patients with Advanced Malignant Solid Tumors
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsAdvanced Solid Tumors
CountriesChina
CollaboratorsPeking University Cancer Hospital & Institute
Timeline
Phase 1Not Yet Recruiting
20272028
First PostedMar 2026
Enrollment StartApr 2026
TodayJul 2026
Primary CompletionDec 2026
Study CompletionApr 2028
First PostedMar 19, 2026
Enrollment StartApr 1, 2026
Primary CompletionDec 1, 2026
Study CompletionApr 1, 2028
TodayJul 1, 2026
Enrollment to primary: 8 monthsPosted 3 months agoPrimary completion in 5 months
Interventions
GK01 injectiondrug
Autologous tumor-reactive T cells injection